Octagam 10% therapy in COVID-19 patients with severe disease progression - Trial 2020-002482-34
Access comprehensive clinical trial information for 2020-002482-34 through Pure Global AI's free database. This phase not specified trial is sponsored by Octapharma USA and is currently status unknown. The study focuses on COVID-19.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Octapharma USA
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
The primary endpoint is stabilization or improvement in clinical status defined as maintenance or improvement by one category on a 6-category clinical status scale on Day 7.
ICD-10 Classifications
Data Source
EU Clinical Trials Register
2020-002482-34
Non-Device Trial